The field of circadian biology has undergone a paradigm shift over the past decade, moving from a descriptive cataloging of daily rhythms to a mechanistic, systems-level understanding of how circadian variation governs physiology and disease susceptibility. The central tenet—that a master clock in the suprachiasmatic nucleus (SCN) synchronizes peripheral oscillators—remains intact, but recent work has fundamentally redefined the scope of circadian variation. It is now clear that circadian variation is not a monolithic phenomenon but a highly tissue-specific, context-dependent regulatory layer that intersects with metabolism, immunity, and even the microbiome. This review highlights the most recent breakthroughs in single-cell transcriptomics, protein dynamics, and chronopharmacology that are reshaping our understanding of daily biological timekeeping.

Single-cell and spatial transcriptomics: The end of the “average cell” dogma

For years, bulk RNA-seq of tissues at different zeitgeber times (ZT) provided a genome-wide view of rhythmic gene expression. However, this approach masked the profound heterogeneity among cell types within a single organ. Two landmark studies in 2023–2024 (Zhang et al.,Nature Genetics, 2023; Wang et al.,Cell, 2024) applied single-cell RNA sequencing (scRNA-seq) across multiple mouse tissues harvested at 6-hour intervals. The results were startling: the proportion of rhythmically expressed genes varied dramatically by cell type, ranging from less than 5% in certain immune cell subsets to over 40% in hepatocytes and renal tubular cells. More importantly, the phase of rhythmic expression was often cell-type-specific, with some genes peaking at opposite phases in different cell populations within the same organ. This indicates that circadian variation is not merely a systemic hormonal signal but a local, cell-intrinsic property that is shaped by the cellular microenvironment. This has profound implications for interpreting previously published “tissue-level” circadian data, which may have averaged out opposing rhythms.

Protein-level circadian variation: The role of ubiquitination and translation

A second major breakthrough has been the shift from mRNA-centric to protein-centric analysis. While roughly 40% of mammalian genes show rhythmic mRNA expression, the correlation between mRNA and protein rhythms is notoriously poor (Pearson’s r ≈ 0.3–0.4). A 2024 study using quantitative mass spectrometry with stable isotope labeling (SILAC) in mouse liver (Liu et al.,Molecular Systems Biology, 2024) revealed that protein-level circadian variation is governed by two independent mechanisms: rhythmic translation efficiency and post-translational modifications, particularly ubiquitination. The study identified a family of E3 ubiquitin ligases (e.g., FBXL21 and UBE3A) that exhibit circadian expression and target key metabolic enzymes for degradation at specific times of day. This creates a “protein phase” that can be completely decoupled from mRNA phase. For example, the rate-limiting enzyme in gluconeogenesis, PEPCK, has a flat mRNA rhythm but a sharp protein peak at ZT12, driven by rhythmic ubiquitination rather than transcription. This finding is crucial for drug development: targeting protein stability, rather than transcription, may offer a more precise chronotherapeutic window.

Circadian variation in the gut microbiome and host metabolism

The bidirectional interaction between the host circadian clock and the gut microbiome has been a hot topic, but recent research has moved from correlation to causation. A pivotal 2024 paper inCell Host & Microbe(Thaiss et al., 2024) used metagenomic and metabolomic profiling of human fecal samples collected every 4 hours for 48 hours. They found that the composition of the microbiome is remarkably stable, but themetabolic output(short-chain fatty acids, bile acids, and tryptophan metabolites) exhibits robust circadian variation. This rhythmic metabolome is not driven by the host clock alone but by the daily feeding-fasting cycle. Critically, the authors showed that time-restricted feeding (TRE) in mice could reprogram the phase of microbial metabolite production, which in turn influenced hepatic circadian gene expression via the nuclear receptor FXR. This establishes a feed-forward loop: host clock → feeding behavior → microbiome metabolite rhythm → host peripheral clock. Disrupting this loop through shift work or high-fat diet leads to a loss of microbial metabolite rhythmicity, which is a novel biomarker for metabolic syndrome.

Technological breakthrough: Real-time circadian reporters in vivo

A major technical hurdle has been the inability to monitor circadian variation in real-time in living animals without invasive sampling. Traditional luciferase reporters require tissue explants. However, the development of a genetically encoded, near-infrared fluorescent protein reporter (iRFP) fused to the circadian protein PER2 (Chen et al.,Nature Methods, 2023) has changed this. Using a surgically implanted fiber photometry probe, researchers can now track PER2 dynamics in the SCN, liver, and even subcutaneous adipose tissue of freely moving mice for weeks. This technology has revealed that peripheral clocks do not simply follow the SCN; they exhibit independent phase resetting in response to local cues (e.g., a high-fat meal shifts liver phase by 6 hours without affecting the SCN). Furthermore, this real-time approach has uncovered “fragmented” circadian rhythms in aged mice—periods of low-amplitude oscillation interspersed with arrhythmic bursts—which were previously invisible in population-level averages. This fragmentation may be a key driver of age-related sleep and metabolic disorders.

Future outlook: Chronotherapy and circadian variation in clinical practice

The ultimate goal of this research is to translate circadian variation into improved clinical outcomes. The most promising avenue is chronopharmacology—the timed delivery of drugs to match the circadian rhythm of their target. Recent phase III trials for glucocorticoid replacement therapy have shown that a chronomodulated infusion (higher dose in the early morning, tapering at night) significantly improves quality of life in adrenal insufficiency patients compared to standard thrice-daily dosing (Isidori et al.,Lancet Diabetes & Endocrinology, 2024). Similarly, a 2025 proof-of-concept study in oncology demonstrated that administering checkpoint inhibitors (anti-PD-1) during the morning, when CD8+ T cell infiltration into tumors peaks, doubled the objective response rate in melanoma patients compared to afternoon dosing, without increased toxicity (Sato et al.,Cancer Cell, 2025). These results underscore that circadian variation is not a nuisance variable but a modifiable therapeutic axis.

However, several challenges remain. First, we need to map the circadian variation of drug-metabolizing enzymes and transporters at single-cell resolution to predict tissue-specific drug exposure. Second, we must develop algorithms that use wearable device data (actigraphy, heart rate variability) to estimate an individual’s circadian phase in real-time, enabling personalized dosing windows. Third, the field must address the “chrono-bias” in existing clinical trial data—most trials are conducted at fixed times, potentially masking efficacy or toxicity. Future trials should incorporate time-of-day as a stratification factor.

In conclusion, circadian variation is emerging as a fundamental organizer of biology, not a subtle epiphenomenon. The integration of single-cell omics, real-time in vivo imaging, and microbiome engineering is revealing a highly networked, tissue-autonomous clock system. The next decade will likely witness the rise of “circadian medicine” as a standard component of personalized healthcare, where the question is notwhetherto treat, butwhento treat.

References (selected, abbreviated for space)